Share Price and Basic Stock Data
Last Updated: January 14, 2026, 8:31 pm
| PEG Ratio | -19.64 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Biocon Ltd, a prominent player in the pharmaceuticals industry, reported a share price of ₹383 and a market capitalization of ₹57,788 Cr. The company’s revenue from operations for the trailing twelve months (TTM) stood at ₹16,476 Cr, reflecting a robust growth trajectory compared to ₹11,174 Cr in FY 2023. The quarterly sales figures exhibited a consistent upward trend, with revenues increasing from ₹2,320 Cr in September 2022 to ₹3,462 Cr in September 2023, and further rising to ₹3,954 Cr in December 2023. This growth is indicative of Biocon’s effective market strategies and product portfolio expansion. The company’s operating profit margin (OPM) averaged 21% over the last four quarters, underscoring effective cost management despite a competitive landscape. The increasing sales indicate a strong demand for Biocon’s biopharmaceutical products, positioning the company favorably within the Indian pharma sector.
Profitability and Efficiency Metrics
In terms of profitability, Biocon’s net profit for FY 2025 was reported at ₹1,429 Cr, a significant increase from ₹643 Cr in FY 2023. The net profit margin stood at 9.36%, reflecting a healthy profitability level compared to industry averages. The return on equity (ROE) was reported at 4.68%, while return on capital employed (ROCE) was 6.04%, both of which are lower than the typical sector benchmarks but indicative of the company’s ability to generate returns on its investments. The interest coverage ratio (ICR) was a solid 4.87x, demonstrating Biocon’s capacity to meet interest obligations comfortably. However, the company’s operating profit margin, which peaked at 25% in March 2023, has seen some volatility, suggesting potential challenges in maintaining operational efficiency amidst rising costs.
Balance Sheet Strength and Financial Ratios
Biocon’s balance sheet reflects a total asset base of ₹58,540 Cr, with total liabilities of ₹58,540 Cr, resulting in a debt-to-equity ratio of 0.82x. This indicates a moderate level of leverage compared to industry standards. Reserves have grown significantly to ₹26,135 Cr as of September 2025, showcasing the company’s ability to retain earnings and bolster its financial position. Borrowings, however, stood at ₹16,536 Cr, which, while manageable, suggests that the company is reliant on debt for its expansion plans. The current ratio of 1.14 indicates adequate liquidity to meet short-term obligations, while the quick ratio of 0.79 suggests a need for caution regarding immediate liquidity. Overall, Biocon’s financial ratios reflect a balanced approach to growth, although maintaining a prudent debt level remains crucial.
Shareholding Pattern and Investor Confidence
The shareholding structure of Biocon indicates a strong promoter presence, with promoters holding 54.45% of the total shares, down from 60.64% earlier, which may signal a gradual dilution of control. Foreign institutional investors (FIIs) held 6.61%, while domestic institutional investors (DIIs) increased their stake to 22.06%, reflecting heightened confidence among domestic investors. The total number of shareholders reached 413,191, indicating growing public interest in the stock. The dividend payout ratio stood at 5.92%, suggesting a conservative approach to returning capital to shareholders, which aligns with the company’s focus on reinvesting earnings for growth. This evolving shareholding pattern, combined with a diverse investor base, bodes well for future capital raising and strategic initiatives.
Outlook, Risks, and Final Insight
Looking ahead, Biocon’s growth prospects appear positive, driven by expanding product offerings and a solid revenue growth trajectory. However, risks such as increasing competition, regulatory challenges, and dependence on external financing could hinder performance. The company’s ability to maintain profitability amidst rising costs will be crucial. Biocon must also navigate potential market fluctuations and operational efficiencies to sustain its growth momentum. Given the current landscape, the company may consider strategic partnerships and innovation to mitigate risks and capitalize on opportunities. In a favorable scenario, if Biocon can leverage its strengths and address its challenges effectively, it could enhance shareholder value and solidify its position as a leader in the biopharmaceutical sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 130 Cr. | 103 | 208/84.3 | 28.7 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,079 Cr. | 374 | 479/192 | 84.5 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.3 Cr. | 44.8 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,219.38 Cr | 1,122.28 | 52.68 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,320 | 2,941 | 3,774 | 3,423 | 3,462 | 3,954 | 3,917 | 3,433 | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 |
| Expenses | 1,877 | 2,352 | 2,817 | 2,741 | 2,745 | 3,051 | 3,004 | 2,812 | 2,905 | 3,070 | 3,339 | 3,193 | 3,460 |
| Operating Profit | 442 | 589 | 957 | 681 | 717 | 903 | 913 | 620 | 685 | 752 | 1,078 | 749 | 835 |
| OPM % | 19% | 20% | 25% | 20% | 21% | 23% | 23% | 18% | 19% | 20% | 24% | 19% | 19% |
| Other Income | 48 | -193 | 152 | 94 | 134 | 587 | 40 | 1,166 | 58 | 53 | 57 | 80 | 81 |
| Interest | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 | 272 |
| Depreciation | 231 | 301 | 364 | 358 | 389 | 414 | 407 | 405 | 420 | 425 | 436 | 455 | 473 |
| Profit before tax | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 | 171 |
| Tax % | 64% | -19% | 17% | 19% | 19% | 7% | 30% | 25% | 72% | 48% | 6% | 8% | 22% |
| Net Profit | 82 | -21 | 414 | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 | 133 |
| EPS in Rs | 0.39 | -0.35 | 2.61 | 0.84 | 1.05 | 5.50 | 1.13 | 5.49 | -0.13 | 0.21 | 2.87 | 0.23 | 0.63 |
Last Updated: January 2, 2026, 6:03 am
Below is a detailed analysis of the quarterly data for Biocon Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 4,296.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,942.00 Cr. (Jun 2025) to 4,296.00 Cr., marking an increase of 354.00 Cr..
- For Expenses, as of Sep 2025, the value is 3,460.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,193.00 Cr. (Jun 2025) to 3,460.00 Cr., marking an increase of 267.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 835.00 Cr.. The value appears strong and on an upward trend. It has increased from 749.00 Cr. (Jun 2025) to 835.00 Cr., marking an increase of 86.00 Cr..
- For OPM %, as of Sep 2025, the value is 19.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 19.00%.
- For Other Income, as of Sep 2025, the value is 81.00 Cr.. The value appears strong and on an upward trend. It has increased from 80.00 Cr. (Jun 2025) to 81.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 272.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 277.00 Cr. (Jun 2025) to 272.00 Cr., marking a decrease of 5.00 Cr..
- For Depreciation, as of Sep 2025, the value is 473.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 455.00 Cr. (Jun 2025) to 473.00 Cr., marking an increase of 18.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 171.00 Cr.. The value appears strong and on an upward trend. It has increased from 97.00 Cr. (Jun 2025) to 171.00 Cr., marking an increase of 74.00 Cr..
- For Tax %, as of Sep 2025, the value is 22.00%. The value appears to be increasing, which may not be favorable. It has increased from 8.00% (Jun 2025) to 22.00%, marking an increase of 14.00%.
- For Net Profit, as of Sep 2025, the value is 133.00 Cr.. The value appears strong and on an upward trend. It has increased from 89.00 Cr. (Jun 2025) to 133.00 Cr., marking an increase of 44.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.63. The value appears strong and on an upward trend. It has increased from 0.23 (Jun 2025) to 0.63, marking an increase of 0.40.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:33 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,877 | 3,090 | 3,347 | 3,891 | 4,123 | 5,514 | 6,367 | 7,143 | 8,184 | 11,174 | 14,756 | 15,262 | 16,476 |
| Expenses | 2,190 | 2,394 | 2,957 | 2,912 | 3,294 | 4,121 | 4,792 | 5,562 | 6,391 | 8,762 | 11,540 | 12,008 | 13,062 |
| Operating Profit | 687 | 696 | 390 | 980 | 829 | 1,394 | 1,575 | 1,581 | 1,793 | 2,412 | 3,216 | 3,254 | 3,414 |
| OPM % | 24% | 23% | 12% | 25% | 20% | 25% | 25% | 22% | 22% | 22% | 22% | 21% | 21% |
| Other Income | 56 | 158 | 639 | 173 | 228 | 340 | 228 | 260 | 72 | 18 | 853 | 1,217 | 271 |
| Interest | 2 | 9 | 29 | 26 | 62 | 71 | 65 | 58 | 68 | 419 | 974 | 897 | 985 |
| Depreciation | 204 | 221 | 249 | 277 | 385 | 448 | 552 | 715 | 814 | 1,113 | 1,569 | 1,687 | 1,790 |
| Profit before tax | 538 | 624 | 751 | 850 | 610 | 1,215 | 1,186 | 1,068 | 983 | 897 | 1,525 | 1,887 | 911 |
| Tax % | 20% | 15% | 19% | 19% | 26% | 17% | 27% | 21% | 22% | 28% | 15% | 24% | |
| Net Profit | 431 | 528 | 609 | 688 | 453 | 1,003 | 871 | 846 | 772 | 643 | 1,298 | 1,429 | 762 |
| EPS in Rs | 3.45 | 4.14 | 4.59 | 5.10 | 3.10 | 7.54 | 6.24 | 6.17 | 5.40 | 3.85 | 8.52 | 8.44 | 3.94 |
| Dividend Payout % | 24% | 20% | 18% | 10% | 16% | 7% | 0% | 0% | 9% | 39% | 6% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 22.51% | 15.34% | 12.97% | -34.16% | 121.41% | -13.16% | -2.87% | -8.75% | -16.71% | 101.87% | 10.09% |
| Change in YoY Net Profit Growth (%) | 0.00% | -7.16% | -2.37% | -47.13% | 155.57% | -134.57% | 10.29% | -5.88% | -7.96% | 118.58% | -91.77% |
Biocon Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 19% |
| 3 Years: | 23% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 7% |
| 3 Years: | 10% |
| TTM: | -77% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | -3% |
| 3 Years: | 7% |
| 1 Year: | -6% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 5% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 1:00 am
Balance Sheet
Last Updated: December 4, 2025, 1:03 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 100 | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 | 668 |
| Reserves | 2,927 | 3,171 | 3,934 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 | 21,044 | 26,135 |
| Borrowings | 864 | 1,117 | 2,478 | 2,302 | 2,264 | 2,422 | 2,715 | 4,481 | 5,147 | 18,019 | 16,277 | 18,362 | 16,536 |
| Other Liabilities | 1,860 | 1,988 | 1,947 | 2,254 | 2,545 | 3,672 | 4,993 | 6,382 | 6,763 | 15,856 | 19,693 | 18,534 | 19,421 |
| Total Liabilities | 5,751 | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,414 | 18,490 | 20,342 | 51,742 | 55,753 | 58,540 | 62,760 |
| Fixed Assets | 1,525 | 1,630 | 1,748 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 | 31,963 | 37,262 |
| CWIP | 1,206 | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 | 8,508 | 4,651 |
| Investments | 765 | 230 | 902 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 | 1,127 | 2,333 |
| Other Assets | 2,255 | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,281 | 7,374 | 8,074 | 12,888 | 16,117 | 16,941 | 18,513 |
| Total Assets | 5,751 | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,414 | 18,490 | 20,342 | 51,742 | 55,753 | 58,540 | 62,760 |
Below is a detailed analysis of the balance sheet data for Biocon Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 668.00 Cr.. The value appears strong and on an upward trend. It has increased from 600.00 Cr. (Mar 2025) to 668.00 Cr., marking an increase of 68.00 Cr..
- For Reserves, as of Sep 2025, the value is 26,135.00 Cr.. The value appears strong and on an upward trend. It has increased from 21,044.00 Cr. (Mar 2025) to 26,135.00 Cr., marking an increase of 5,091.00 Cr..
- For Borrowings, as of Sep 2025, the value is 16,536.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 18,362.00 Cr. (Mar 2025) to 16,536.00 Cr., marking a decrease of 1,826.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 19,421.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18,534.00 Cr. (Mar 2025) to 19,421.00 Cr., marking an increase of 887.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 62,760.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 58,540.00 Cr. (Mar 2025) to 62,760.00 Cr., marking an increase of 4,220.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 37,262.00 Cr.. The value appears strong and on an upward trend. It has increased from 31,963.00 Cr. (Mar 2025) to 37,262.00 Cr., marking an increase of 5,299.00 Cr..
- For CWIP, as of Sep 2025, the value is 4,651.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8,508.00 Cr. (Mar 2025) to 4,651.00 Cr., marking a decrease of 3,857.00 Cr..
- For Investments, as of Sep 2025, the value is 2,333.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,127.00 Cr. (Mar 2025) to 2,333.00 Cr., marking an increase of 1,206.00 Cr..
- For Other Assets, as of Sep 2025, the value is 18,513.00 Cr.. The value appears strong and on an upward trend. It has increased from 16,941.00 Cr. (Mar 2025) to 18,513.00 Cr., marking an increase of 1,572.00 Cr..
- For Total Assets, as of Sep 2025, the value is 62,760.00 Cr.. The value appears strong and on an upward trend. It has increased from 58,540.00 Cr. (Mar 2025) to 62,760.00 Cr., marking an increase of 4,220.00 Cr..
Notably, the Reserves (26,135.00 Cr.) exceed the Borrowings (16,536.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -177.00 | 695.00 | 388.00 | 978.00 | 827.00 | -1.00 | -1.00 | -3.00 | -4.00 | -16.00 | -13.00 | -15.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 76 | 91 | 78 | 83 | 94 | 86 | 71 | 77 | 92 | 117 | 154 | 131 |
| Inventory Days | 116 | 132 | 153 | 160 | 161 | 199 | 263 | 304 | 309 | 423 | 368 | 346 |
| Days Payable | 107 | 125 | 172 | 187 | 224 | 231 | 243 | 246 | 216 | 383 | 467 | 460 |
| Cash Conversion Cycle | 85 | 98 | 59 | 57 | 31 | 53 | 91 | 134 | 184 | 157 | 55 | 18 |
| Working Capital Days | -31 | -19 | -12 | 24 | 6 | -2 | -31 | 8 | 71 | 3 | -68 | -63 |
| ROCE % | 15% | 12% | 9% | 12% | 8% | 13% | 12% | 10% | 9% | 6% | 6% | 6% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Contra Fund | 28,807,465 | 2.3 | 1147.55 | 16,770,774 | 2025-12-08 00:57:08 | 71.77% |
| SBI Midcap Fund | 13,969,697 | 2.38 | 556.48 | N/A | N/A | N/A |
| Kotak Large & Midcap Fund | 13,000,000 | 1.73 | 517.86 | N/A | N/A | N/A |
| SBI Balanced Advantage Fund | 10,021,205 | 1.01 | 399.19 | 10,021,205 | 2025-04-22 17:25:40 | 0% |
| SBI Large & Midcap Fund | 9,576,988 | 1.03 | 381.5 | N/A | N/A | N/A |
| Nippon India Focused Fund | 6,359,471 | 2.85 | 253.33 | 7,299,915 | 2025-12-14 04:35:41 | -12.88% |
| Nippon India Multi Cap Fund | 6,026,895 | 0.48 | 240.08 | 9,326,895 | 2025-12-15 04:02:53 | -35.38% |
| Franklin India Mid Cap Fund | 5,862,280 | 1.81 | 233.52 | N/A | N/A | N/A |
| Mirae Asset Midcap Fund | 4,569,066 | 0.99 | 182.01 | 4,792,542 | 2025-12-14 04:35:41 | -4.66% |
| Nippon India Pharma Fund | 4,219,374 | 1.99 | 168.08 | 4,719,374 | 2025-12-14 04:35:41 | -10.59% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 8.46 | 8.55 | 3.88 | 5.44 | 6.24 |
| Diluted EPS (Rs.) | 8.46 | 8.54 | 3.87 | 5.42 | 6.19 |
| Cash EPS (Rs.) | 25.96 | 24.58 | 16.02 | 14.93 | 13.59 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 180.27 | 210.51 | 187.31 | 78.87 | 70.09 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 180.28 | 210.52 | 187.31 | 78.88 | 70.10 |
| Revenue From Operations / Share (Rs.) | 127.12 | 122.90 | 93.07 | 68.17 | 59.22 |
| PBDIT / Share (Rs.) | 36.44 | 34.68 | 24.05 | 18.18 | 15.89 |
| PBIT / Share (Rs.) | 22.38 | 21.62 | 14.78 | 11.40 | 9.93 |
| PBT / Share (Rs.) | 15.71 | 13.40 | 8.86 | 9.91 | 9.56 |
| Net Profit / Share (Rs.) | 11.91 | 11.51 | 6.75 | 8.15 | 7.63 |
| NP After MI And SOA / Share (Rs.) | 8.44 | 8.52 | 3.85 | 5.40 | 6.17 |
| PBDIT Margin (%) | 28.66 | 28.22 | 25.84 | 26.67 | 26.83 |
| PBIT Margin (%) | 17.60 | 17.58 | 15.88 | 16.72 | 16.77 |
| PBT Margin (%) | 12.36 | 10.90 | 9.52 | 14.54 | 16.14 |
| Net Profit Margin (%) | 9.36 | 9.36 | 7.24 | 11.95 | 12.88 |
| NP After MI And SOA Margin (%) | 6.63 | 6.92 | 4.14 | 7.92 | 10.42 |
| Return on Networth / Equity (%) | 4.68 | 5.16 | 2.58 | 7.69 | 9.83 |
| Return on Capital Employeed (%) | 6.04 | 6.37 | 4.07 | 8.26 | 8.32 |
| Return On Assets (%) | 1.72 | 1.82 | 0.88 | 3.17 | 3.99 |
| Long Term Debt / Equity (X) | 0.57 | 0.65 | 0.85 | 0.47 | 0.39 |
| Total Debt / Equity (X) | 0.82 | 0.79 | 0.99 | 0.58 | 0.47 |
| Asset Turnover Ratio (%) | 0.26 | 0.27 | 0.30 | 0.12 | 0.17 |
| Current Ratio (X) | 1.14 | 0.98 | 1.45 | 2.19 | 1.81 |
| Quick Ratio (X) | 0.79 | 0.66 | 0.95 | 1.59 | 1.36 |
| Inventory Turnover Ratio (X) | 3.09 | 1.10 | 0.97 | 0.75 | 0.81 |
| Dividend Payout Ratio (NP) (%) | 5.92 | 17.61 | 12.96 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 2.22 | 6.95 | 3.80 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 94.08 | 82.39 | 87.04 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 97.78 | 93.05 | 96.20 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 4.87 | 4.27 | 6.89 | 32.29 | 33.05 |
| Interest Coverage Ratio (Post Tax) (X) | 2.49 | 2.43 | 3.63 | 17.12 | 16.82 |
| Enterprise Value (Cr.) | 60668.27 | 50669.85 | 44766.88 | 44360.07 | 51477.10 |
| EV / Net Operating Revenue (X) | 3.98 | 3.43 | 4.01 | 5.42 | 7.24 |
| EV / EBITDA (X) | 13.87 | 12.17 | 15.50 | 20.32 | 26.99 |
| MarketCap / Net Operating Revenue (X) | 2.68 | 2.15 | 2.22 | 4.91 | 6.90 |
| Retention Ratios (%) | 94.07 | 82.38 | 87.03 | 0.00 | 0.00 |
| Price / BV (X) | 1.89 | 1.60 | 1.39 | 4.76 | 6.51 |
| Price / Net Operating Revenue (X) | 2.68 | 2.15 | 2.22 | 4.91 | 6.90 |
| EarningsYield | 0.02 | 0.03 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Biocon Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.46. This value is within the healthy range. It has decreased from 8.55 (Mar 24) to 8.46, marking a decrease of 0.09.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.46. This value is within the healthy range. It has decreased from 8.54 (Mar 24) to 8.46, marking a decrease of 0.08.
- For Cash EPS (Rs.), as of Mar 25, the value is 25.96. This value is within the healthy range. It has increased from 24.58 (Mar 24) to 25.96, marking an increase of 1.38.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 180.27. It has decreased from 210.51 (Mar 24) to 180.27, marking a decrease of 30.24.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 180.28. It has decreased from 210.52 (Mar 24) to 180.28, marking a decrease of 30.24.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 127.12. It has increased from 122.90 (Mar 24) to 127.12, marking an increase of 4.22.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 36.44. This value is within the healthy range. It has increased from 34.68 (Mar 24) to 36.44, marking an increase of 1.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is 22.38. This value is within the healthy range. It has increased from 21.62 (Mar 24) to 22.38, marking an increase of 0.76.
- For PBT / Share (Rs.), as of Mar 25, the value is 15.71. This value is within the healthy range. It has increased from 13.40 (Mar 24) to 15.71, marking an increase of 2.31.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 11.91. This value is within the healthy range. It has increased from 11.51 (Mar 24) to 11.91, marking an increase of 0.40.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.44. This value is within the healthy range. It has decreased from 8.52 (Mar 24) to 8.44, marking a decrease of 0.08.
- For PBDIT Margin (%), as of Mar 25, the value is 28.66. This value is within the healthy range. It has increased from 28.22 (Mar 24) to 28.66, marking an increase of 0.44.
- For PBIT Margin (%), as of Mar 25, the value is 17.60. This value is within the healthy range. It has increased from 17.58 (Mar 24) to 17.60, marking an increase of 0.02.
- For PBT Margin (%), as of Mar 25, the value is 12.36. This value is within the healthy range. It has increased from 10.90 (Mar 24) to 12.36, marking an increase of 1.46.
- For Net Profit Margin (%), as of Mar 25, the value is 9.36. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 9.36.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.63. This value is below the healthy minimum of 8. It has decreased from 6.92 (Mar 24) to 6.63, marking a decrease of 0.29.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.68. This value is below the healthy minimum of 15. It has decreased from 5.16 (Mar 24) to 4.68, marking a decrease of 0.48.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.04. This value is below the healthy minimum of 10. It has decreased from 6.37 (Mar 24) to 6.04, marking a decrease of 0.33.
- For Return On Assets (%), as of Mar 25, the value is 1.72. This value is below the healthy minimum of 5. It has decreased from 1.82 (Mar 24) to 1.72, marking a decrease of 0.10.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.57. This value is within the healthy range. It has decreased from 0.65 (Mar 24) to 0.57, marking a decrease of 0.08.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.82. This value is within the healthy range. It has increased from 0.79 (Mar 24) to 0.82, marking an increase of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.26. It has decreased from 0.27 (Mar 24) to 0.26, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 1.5. It has increased from 0.98 (Mar 24) to 1.14, marking an increase of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 0.79. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.79, marking an increase of 0.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.09. This value is below the healthy minimum of 4. It has increased from 1.10 (Mar 24) to 3.09, marking an increase of 1.99.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 5.92. This value is below the healthy minimum of 20. It has decreased from 17.61 (Mar 24) to 5.92, marking a decrease of 11.69.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 2.22. This value is below the healthy minimum of 20. It has decreased from 6.95 (Mar 24) to 2.22, marking a decrease of 4.73.
- For Earning Retention Ratio (%), as of Mar 25, the value is 94.08. This value exceeds the healthy maximum of 70. It has increased from 82.39 (Mar 24) to 94.08, marking an increase of 11.69.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 97.78. This value exceeds the healthy maximum of 70. It has increased from 93.05 (Mar 24) to 97.78, marking an increase of 4.73.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.87. This value is within the healthy range. It has increased from 4.27 (Mar 24) to 4.87, marking an increase of 0.60.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.49. This value is below the healthy minimum of 3. It has increased from 2.43 (Mar 24) to 2.49, marking an increase of 0.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 60,668.27. It has increased from 50,669.85 (Mar 24) to 60,668.27, marking an increase of 9,998.42.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.98. This value exceeds the healthy maximum of 3. It has increased from 3.43 (Mar 24) to 3.98, marking an increase of 0.55.
- For EV / EBITDA (X), as of Mar 25, the value is 13.87. This value is within the healthy range. It has increased from 12.17 (Mar 24) to 13.87, marking an increase of 1.70.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.68. This value is within the healthy range. It has increased from 2.15 (Mar 24) to 2.68, marking an increase of 0.53.
- For Retention Ratios (%), as of Mar 25, the value is 94.07. This value exceeds the healthy maximum of 70. It has increased from 82.38 (Mar 24) to 94.07, marking an increase of 11.69.
- For Price / BV (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 1.89, marking an increase of 0.29.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.68. This value is within the healthy range. It has increased from 2.15 (Mar 24) to 2.68, marking an increase of 0.53.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Biocon Ltd:
- Net Profit Margin: 9.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.04% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.68% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.49
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.79
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 120 (Industry average Stock P/E: 52.68)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.82
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.36%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 20th K.M. Hosur Road, Electronics City, Bengaluru Karnataka 560100 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Ms. Kiran Mazumdar Shaw | Executive Chairperson |
| Mr. Siddharth Mittal | Managing Director & CEO |
| Prof. Ravi Rasendra Mazumdar | Non Exe.Non Ind.Director |
| Mr. Eric Vivek Mazumdar | Non Exe.Non Ind.Director |
| Mr. Bobby Kanubhai Parikh | Independent Director |
| Mr. Naina Lal Kidwai | Lead Independent Director |
| Ms. Rekha Mehrotra Menon | Independent Director |
| Mr. Nicholas Robert Haggar | Independent Director |
| Mr. Atul Dhawan | Independent Director |
FAQ
What is the intrinsic value of Biocon Ltd?
Biocon Ltd's intrinsic value (as of 15 January 2026) is ₹915.11 which is 141.45% higher the current market price of ₹379.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹57,162 Cr. market cap, FY2025-2026 high/low of ₹425/291, reserves of ₹26,135 Cr, and liabilities of ₹62,760 Cr.
What is the Market Cap of Biocon Ltd?
The Market Cap of Biocon Ltd is 57,162 Cr..
What is the current Stock Price of Biocon Ltd as on 15 January 2026?
The current stock price of Biocon Ltd as on 15 January 2026 is ₹379.
What is the High / Low of Biocon Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Biocon Ltd stocks is ₹425/291.
What is the Stock P/E of Biocon Ltd?
The Stock P/E of Biocon Ltd is 120.
What is the Book Value of Biocon Ltd?
The Book Value of Biocon Ltd is 200.
What is the Dividend Yield of Biocon Ltd?
The Dividend Yield of Biocon Ltd is 0.13 %.
What is the ROCE of Biocon Ltd?
The ROCE of Biocon Ltd is 6.25 %.
What is the ROE of Biocon Ltd?
The ROE of Biocon Ltd is 4.76 %.
What is the Face Value of Biocon Ltd?
The Face Value of Biocon Ltd is 5.00.